| Display title | Chemistry:1-Aminomethyl-5-methoxyindane |
| Default sort key | Aminomethyl-5-methoxyindane, 1- |
| Page length (in bytes) | 2,775 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 522242 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Carolyn |
| Date of page creation | 08:01, 6 March 2023 |
| Latest editor | imported>Carolyn |
| Date of latest edit | 08:01, 6 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | 1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity to DFMDA. |
